

Tara C Mitchell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6313165/publications.pdf>

Version: 2024-02-01

35
papers

5,389
citations

361413

20
h-index

434195

31
g-index

35
all docs

35
docs citations

35
times ranked

9231
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Nivolumab or Ipilimumab + Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
2	BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced <i>BRAF</i> V600 <i>E</i> -mutant Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 1098-1106.	7.0	32
3	ICAM-1-mediated adhesion is a prerequisite for exosome-induced T _H 1 cell suppression. <i>Developmental Cell</i> , 2022, 57, 329-343.e7.	7.0	42
4	Human epigenetic and transcriptional T _H 1 cell differentiation atlas for identifying functional T _H 1 cell-specific enhancers. <i>Immunity</i> , 2022, 55, 557-574.e7.	14.3	47
5	Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy. <i>Oncologist</i> , 2022, 27, 799-808.	3.7	3
6	HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8 ⁺ T-cell infiltration into tumors. <i>Nature Communications</i> , 2022, 13, .	12.8	23
7	Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 162-170.	6.3	81
8	Impact of Tumor-Infiltrating Lymphocytes on Overall Survival in Merkel Cell Carcinoma. <i>Oncologist</i> , 2021, 26, 63-69.	3.7	8
9	Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration "Melanoma Research Alliance Public Workshop. <i>Clinical Cancer Research</i> , 2021, 27, 394-401.	7.0	5
10	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021, 144, 182-191.	2.8	57
11	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). <i>Nature Medicine</i> , 2021, 27, 301-309.	30.7	218
12	Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T _H 1 cells. <i>Cell Reports</i> , 2021, 35, 109120.	6.4	60
13	Compliance with sentinel lymph node biopsy guidelines for invasive melanomas treated with Mohs micrographic surgery. <i>Cancer</i> , 2021, 127, 3591-3598.	4.1	13
14	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. <i>Cancer Research</i> , 2021, 81, 5230-5241.	0.9	9
15	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. <i>European Journal of Cancer</i> , 2021, 157, 391-402.	2.8	13
16	Costimulation of $\hat{3}$ TCR and TLR7/8 promotes $\hat{2}$ T-cell antitumor activity by modulating mTOR pathway and APC function. , 2021, 9, e003339.		14
17	Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 2915-2926.	1.5	11
18	Association of Insurance Status With Presentation, Treatment, and Survival in Melanoma in the Era of Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2020, 43, 8-15.	2.4	16

#	ARTICLE	IF	CITATIONS
19	Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. <i>Molecular Cell</i> , 2020, 77, 633-644.e5.	9.7	45
20	Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma. , 2020, 8, e000974.		49
21	Combining Radiation with Immunotherapy: The University of Pennsylvania Experience. <i>Seminars in Radiation Oncology</i> , 2020, 30, 173-180.	2.2	6
22	Association of Age with Efficacy of Immunotherapy in Metastatic Melanoma. <i>Oncologist</i> , 2020, 25, e381-e385.	3.7	27
23	Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer. <i>Cell Reports</i> , 2020, 33, 108571.	6.4	99
24	Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. <i>Immunity</i> , 2020, 52, 825-841.e8.	14.3	497
25	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	10.7	155
26	TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. <i>Nature</i> , 2019, 571, 211-218.	27.8	934
27	Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. , 2019, 7, 80.		65
28	A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. <i>Nature Medicine</i> , 2019, 25, 454-461.	30.7	466
29	ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. <i>Cancer Discovery</i> , 2019, 9, 396-415.	9.4	71
30	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 4771-4784.	7.0	29
31	Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). <i>Journal of Clinical Oncology</i> , 2018, 36, 3223-3230.	1.6	267
32	A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. <i>British Journal of Cancer</i> , 2018, 119, 1200-1207.	6.4	83
33	Immunotherapy in melanoma. <i>Immunotherapy</i> , 2018, 10, 987-998.	2.0	22
34	Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy. <i>JAMA Dermatology</i> , 2018, 154, 1057.	4.1	86
35	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. <i>Nature</i> , 2018, 560, 382-386.	27.8	1,836